Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Bernardo Queralt"'
Autor:
José E. Alés-Martínez, Rafael López, Maica Galán, Cristina Grávalos, Francisco Javier Ramos, M.J. Méndez-Vidal, Enrique Aranda, Carlos F. Lopez, Maria Alsina, Josep Tabernero, Jordi Giralt, Pilar García-Alfonso, Bernardo Queralt, Inmaculada Ruiz de Mena, Fernando Rivera, Antonio Antón, Alfredo Carrato
Publikováno v:
Targeted Oncology. 13:69-78
Pre-operative chemoradiotherapy using a 5-fluorouracil (5-FU)/cisplatin backbone is widely used to improve surgical outcomes in locoregional oesophageal cancer patients, despite a non-negligible failure rate. We evaluated intensification of this appr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4a606c793f560a9bb0bdef1f5bc00b2
https://doi.org/10.1007/s11523-017-0536-z
https://doi.org/10.1007/s11523-017-0536-z
Publikováno v:
Cancer Treatment Reviews. 58:61-69
Signal transducer and activator of transcription 3 (STAT3) has a prominent role in mediating resistance to conventional chemo-/radio-therapies and modern targeted drugs. While a number of STAT3 inhibitors have been shown to enhance the efficacy of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffeea6400357b5b1b6c4d3d5abcf85e8
https://doi.org/10.1016/j.ctrv.2017.06.003
https://doi.org/10.1016/j.ctrv.2017.06.003
Autor:
Bernardo Queralt, Javier A. Menendez, Joaquim Bosch-Barrera, Begoña Martin-Castillo, Elisabet Cuyàs
Publikováno v:
Oncology Reports. 38:263-270
Patients with wild-type KRAS metastatic colorectal cancer (mCRC) that harbors NRAS activating mutations do not benefit from anti-EGFR therapies. Very little is known about oncogenic NRAS signaling driving mCRC unresponsiveness to the EGFR-directed an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f39ad167a5cd7c271f0ab35c2422416c
https://doi.org/10.3892/or.2017.5682
https://doi.org/10.3892/or.2017.5682
Autor:
Elena Elez, Raquel Comas, Josep Tabernero, Bernardo Queralt, Javier Ros Montañá, Davide Ciardiello, Rodrigo Dienstmann, Ana Vivancos, Rodrigo A. Toledo, Guillem Argiles, Xavier Hernandez Yague, Antonieta Salud Salvia, Nuria Mulet, Jose Luis Cuadra, Hector G. Palmer, Ariadna Garcia, Iosune Baraibar, Giulia Martini, Guillermo Villacampa, Irene Chicote
Publikováno v:
Web of Science
4112 Background: BRAF V600 mt mCRC is an aggressive disease with poor OS under standard chemotherapy. Treatment with doublet and triplet targeted combinations, such as BRAF inhibitor+ antiEGFR+/- MEK inhibitor, has been shown to improve outcomes. Pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::460c4929c7a604858bbd7c7617691d71
https://doi.org/10.1200/jco.2020.38.15_suppl.4112
https://doi.org/10.1200/jco.2020.38.15_suppl.4112
Autor:
Anna Massaguer, Javier A. Menendez, Elisabet Cuyàs, Ramon Salazar, Joaquim Bosch-Barrera, Bernardo Queralt, Begoña Martin-Castillo, Rafael de Llorens, Joan Brunet
Publikováno v:
Oncotarget, 2016, vol. 7, núm. 50, p. 82185-82199
Articles publicats (D-CM)
DUGiDocs – Universitat de Girona
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Oncotarget
Recercat. Dipósit de la Recerca de Catalunya
Articles publicats (D-CM)
DUGiDocs – Universitat de Girona
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Oncotarget
Recercat. Dipósit de la Recerca de Catalunya
KRAS mutations are an established predictor of lack of response to EGFR-targeted therapies in patients with metastatic colorectal cancer (mCRC). However, little is known about the role of the rarer NRAS mutations as a mechanism of primary resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::784d91ca83c4e58f9cc76a0fa7a69624
https://hdl.handle.net/2072/319591
https://hdl.handle.net/2072/319591
Autor:
X. Hernandez-Yagüe, R. Guardeño, Santiago López-Ben, Juan Figueras, M. Albiol, Maria Alsina, A. Codina-Barreras, Jordi Soriano, Bernardo Queralt
Publikováno v:
Clinical and Translational Oncology. 15:460-466
This prospective observational study assessed the efficacy of bevacizumab in combination with chemotherapy as preoperative treatment to downsize tumours for radical resection in patients with unresectable metastatic colorectal cancer (mCRC). Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d949f22671166863b7cfd5280ec595a2
https://doi.org/10.1007/s12094-012-0952-6
https://doi.org/10.1007/s12094-012-0952-6
Autor:
Carles Pericay, Ma José Gómez, Bernardo Queralt, R. Dueñas, Bartomeu Massuti, Alfredo Carrato, Eugenio Marcuello, Inmaculada Guasch, J. Alfaro, A. Gomez, Arantxa Etxeberría, Manuel Benavides, Jorge Aparicio, Enrique Aranda, Enrique Cabrera, Manuel Valladares-Ayerbes, Silvia Gil-Calle, Juan José Reina, J. M. Campos, Encarna González-Flores
Publikováno v:
Clinical Colorectal Cancer. 11:200-206
Background We previously reported a 35% overall response rate (ORR) with biweekly 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) plus irinotecan as first-line therapy in elderly patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a35b2c9ec2ef9d113b44ddfb6efb0354
https://doi.org/10.1016/j.clcc.2012.01.003
https://doi.org/10.1016/j.clcc.2012.01.003
Autor:
Xavier Hernández-Yagüe, Javier A. Menendez, Alejandro Vazquez-Martin, Bernardo Queralt, Cristina Oliveras-Ferraros, Begoña Martin-Castillo, Raquel Guardeño, Luciana Báez, Sílvia Cufí, Joan Brunet
Publikováno v:
Journal of Cellular Biochemistry. 112:10-29
Beyond a well-recognized effect of KRAS mutations in determining de novo inefficacy of cetuximab (CTX) in metastatic colorectal cancer, we urgently need a biomarker signature for predicting CTX efficacy in KRAS wild-type (WT) tumors. CTX-adapted EGFR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6e564544eb47f8332026c3f2faf0fd4
https://doi.org/10.1002/jcb.22952
https://doi.org/10.1002/jcb.22952
Autor:
Jose Tabernero, Juan José Reina, Jorge Aparicio, Encarnación González-Flores, Alfredo Carrato, Eduardo Díaz-Rubio, M. Chaves, Enrique Aranda, Auxiliadora Gómez-España, Ferran Losa, Bartomeu Massuti, Fernando Rivera, Alberto Abad, Joan Maurel, Javier Sastre, Bernardo Queralt
Publikováno v:
Journal of Clinical Oncology. 25:4224-4230
Purpose The aim of this phase III trial was to compare the efficacy and safety of capecitabine plus oxaliplatin (XELOX) versus Spanish-based continuous-infusion high-dose fluorouracil (FU) plus oxaliplatin (FUOX) regimens as first-line therapy for me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f499f95034b381177777b71aacacc8dd
https://doi.org/10.1200/jco.2006.09.8467
https://doi.org/10.1200/jco.2006.09.8467
Autor:
Manuel Chaves, Andrés Muñoz, Encarna González-Flores, Antonieta Salud, Bernardo Queralt, Amelia López-Ladrón, Enrique Aranda, Maria Jose Gómez, A. Oltra, Pilar García-Alfonso, Maria García-Gonzalez, Ferran Losa, Bartomeu Massuti, Cristina Grávalos
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Recercat. Dipósit de la Recerca de Catalunya
instname
BMC Cancer
Repositorio Abierto de la UdL
Universitad de Lleida
Consejería de Sanidad de la Comunidad de Madrid
Recercat. Dipósit de la Recerca de Catalunya
instname
BMC Cancer
Repositorio Abierto de la UdL
Universitad de Lleida
Background The optimal sequence of chemotherapeutic agents is not firmly established for the treatment of metastatic colorectal cancer (mCRC). This phase II multi-centre study investigated the efficacy and tolerability of a standard capecitabine plus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92a923d94afed2eade4fb0c2ea0e0d82
https://hdl.handle.net/20.500.12530/22046
https://hdl.handle.net/20.500.12530/22046